Molecular and pathogenetic aspects of tumor budding in colorectal cancer

Frontiers in Medicine

Volumn 2, Issue MAR, 2015, Pages 11-

  Dawson, Heather ^a   Lugli, Alessandro ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Colorectal cancer; EMT; Immunohistochemistry; Tumor budding; Tumor microenvironment

Indexed keywords

EID: 84942984617     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00011     Document Type: Review

References (84)

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119:1420-8. doi:10.1172/JCI39104
2. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell (2009) 139:871-90. doi:10.1016/j.cell.2009.11.007
3. Zlobec I, Hadrich M, Dawson H, Koelzer VH, Borner M, Mallaev M, et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br J Cancer (2014) 110:1008-13. doi:10.1038/bjc.2013.797
4. Prall F. Tumour budding in colorectal carcinoma. Histopathology (2007) 50:151-62. doi:10.1111/j.1365-2559.2006.02551.x
5. Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R. Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol (2012) 25:1315-25. doi:10.1038/modpathol.2012.94
6. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum (2003) 46:1400-6. doi:10.1007/s10350-004-6757-0
7. Tanaka M, Hashiguchi Y, Ueno H, Hase K, Mochizuki H. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 Colon Cancer. Dis Colon Rectum (2003) 46:1054-9. doi:10.1007/s10350-004-7280-z
8. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum (1993) 36:627-35. doi:10.1007/BF02238588
9. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology (2002) 40:127-32. doi:10.1046/j.1365-2559.2002.01324.x
10. Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Yokoo T, Ishii T, et al. Group for cancer biological, histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer (2008) 112:924-33. doi:10.1002/cncr.23248
11. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology (2005) 52:1432-5.
12. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hyland J, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol (2009) 33:134-41. doi:10.1097/PAS.0b013e318184cd55
13. Gabbert H, Wagner R, Moll R, Gerharz CD. Tumor dedifferentiation: an important step in tumor invasion. Clin Exp Metastasis (1985) 3:257-79. doi:10.1007/BF01585081
14. Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol (2013) 44:697-705. doi:10.1016/j.humpath.2012.07.026
15. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget (2010) 1:651-61.
16. N. Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 487:330-7. doi:10.1038/nature11252
17. Chen D, Huang JF, Liu K, Zhang LQ, Yang Z, Chuai ZR, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One (2014) 9:e90607. doi:10.1371/journal.pone.0090607
18. Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, et al. Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol (2012) 19:1944-53. doi:10.1245/s10434-011-2174-5
19. Jass JR, Barker M, Fraser L, Walsh MD, Whitehall VL, Gabrielli B, et al. APC mutation and tumour budding in colorectal cancer. J Clin Pathol (2003) 56:69-73. doi:10.1136/jcp.56.1.69
20. Zlobec I, Bihl MP, Foerster A, Rufle A, Lugli A. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer. Histopathology (2012) 61:777-87. doi:10.1111/j.1365-2559.2012.04273.x
21. Shinto E, Baker K, Tsuda H, Mochizuki H, Ueno H, Matsubara O, et al. Tumor buds show reduced expression of laminin-5 gamma 2 chain in DNA mismatch repair deficient colorectal cancer. Dis Colon Rectum (2006) 49:1193-202. doi:10.1007/s10350-006-0568-4
22. Garcia-Solano J, Conesa-Zamora P, Trujillo-Santos J, Torres-Moreno D, Makinen MJ, Perez-Guillermo M. Immunohistochemical expression profile of beta-catenin, E-cadherin, P-cadherin, laminin-5gamma2 chain, and SMAD4 in colorectal serrated adenocarcinoma. Hum Pathol (2012) 43:1094-102. doi:10.1016/j.humpath.2011.08.020
23. Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med (2011) 135:698-703. doi:10.1043/2010-0523-RA.1
24. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 105:1151-6. doi:10.1093/jnci/djt173
25. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH, Nagtegaal ID. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol (2007) 20:221-32. doi:10.1038/modpathol.3800733
26. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs (2005) 179:56-65. doi:10.1159/000084509
27. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol Res Pract (1998) 194:701-4. doi:10.1016/S0344-0338(98)80129-5
28. El-Bahrawy MA, Poulsom R, Jeffery R, Talbot I, Alison MR. The expression of E-cadherin and catenins in sporadic colorectal carcinoma. Hum Pathol (2001) 32:1216-24. doi:10.1053/hupa.2001.28948
29. Lauscher JC, Loddenkemper C, Kosel L, Grone J, Buhr HJ, Huber O. Increased pontin expression in human colorectal cancer tissue. Hum Pathol (2007) 38:978-85. doi:10.1016/j.humpath.2007.01.005
30. Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Schlemmer A, Rehak P, et al. Keratin 7 expression in colorectal cancer - freak of nature or significant finding? Histopathology (2011) 59:225-34. doi:10.1111/j.1365-2559.2011.03694.x
31. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA (2001) 98:10356-61. doi:10.1073/pnas.171610498
32. Horkko TT, Klintrup K, Makinen JM, Napankangas JB, Tuominen HJ, Makela J, et al. Budding invasive margin and prognosis in colorectal cancer - no direct association with beta-catenin expression. Eur J Cancer (2006) 42:964-71. doi:10.1016/j.ejca.2006.01.017
33. Karamitopoulou E, Zlobec I, Panayiotides I, Patsouris ES, Peros G, Rallis G, et al. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol (2011) 42:1888-96. doi:10.1016/j.humpath.2010.06.020
34. Jass JR, Young J, Leggett BA. Evolution of colorectal cancer: change of pace and change of direction. J Gastroenterol Hepatol (2002) 17:17-26. doi:10.1046/j.1440-1746.2002.02635.x
35. Karamitopoulou E, Zlobec I, Kolzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol (2013) 26:295-301. doi:10.1038/modpathol.2012.155
36. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology (2005) 47:17-24. doi:10.1111/j.1365-2559.2005.02161.x
37. Morodomi T, Isomoto H, Shirouzu K, Kakegawa K, Irie K, Morimatsu M. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer (1989) 63:539-43. doi:10.1002/1097-0142(19890201)63:3<539::AID-CNCR2820630323>3.0.CO;2-S
38. Guzinska-Ustymowicz K. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res (2006) 26:1589-94.
39. Rubio CA. Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report. Anticancer Res (2008) 28:2417-20.
40. Sordat I, Rousselle P, Chaubert P, Petermann O, Aberdam D, Bosman FT, et al. Tumor cell budding and laminin-5 expression in colorectal carcinoma can be modulated by the tissue micro-environment. Int J Cancer (2000) 88:708-17. doi:10.1002/1097-0215(20001201)88:5<708::AID-IJC5>3.0.CO;2-J
41. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res (2009) 69:5627-9. doi:10.1158/0008-5472.CAN-09-0654
42. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol (2005) 168:633-42. doi:10.1083/jcb.200408051
43. Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, et al. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med (2012) 1:5-16. doi:10.1002/cam4.4
44. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest (2009) 27:844-50. doi:10.1080/07357900902744502
45. Jung A, Schrauder M, Oswald U, Knoll C, Sellberg P, Palmqvist R, et al. The invasion front of human colorectal adenocarcinomas shows co-localization of nuclear beta-catenin, cyclin D1, and p16INK4A and is a region of low proliferation. Am J Pathol (2001) 159:1613-7. doi:10.1016/S0002-9440(10)63007-6
46. Escara-Wilke J, Yeung K, Keller ET. Raf kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev (2012) 31:615-20. doi:10.1007/s10555-012-9365-9
47. Smit MA, Geiger TR, Song JY, Gitelman I, Peeper DS. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol Cell Biol (2009) 29:3722-37. doi:10.1128/MCB.01164-08
48. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol (2007) 28:299-307. doi:10.1016/j.it.2007.05.007
49. Hostettler L, Zlobec I, Terracciano L, Lugli A. ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol (2010) 16:732-9. doi:10.3748/wjg.v16.i6.732
50. Rizzi C, Cataldi P, Iop A, Isola M, Sgarra R, Manfioletti G, et al. The expression of the high-mobility group A2 protein in colorectal cancer and surrounding fibroblasts is linked to tumor invasiveness. Hum Pathol (2013) 44:122-32. doi:10.1016/j.humpath.2012.05.001
51. Karagiannis GS, Berk A, Dimitromanolakis A, Diamandis EP. Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1. Mol Oncol (2013) 7:826-39. doi:10.1016/j.molonc.2013.04.002
52. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci (2010) 123:2135-43. doi:10.1242/jcs.069542
53. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell (2009) 15:416-28. doi:10.1016/j.ccr.2009.03.016
54. Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell (2014) 15:692-705. doi:10.1016/j.stem.2014.11.012
55. Findlay VJ, Wang C, Watson DK, Camp ER. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther (2014) 21:181-7. doi:10.1038/cgt.2014.15
56. Kleist B, Xu L, Li G, Kersten C. Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer. Int J Clin Exp Pathol (2011) 4:327-35.
57. Brabletz T. To differentiate or not - routes towards metastasis. Nat Rev Cancer (2012) 12:425-36. doi:10.1038/nrc3265
58. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene (1997) 14:1329-40. doi:10.1038/sj.onc.1200951
59. Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, et al. The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome. Histopathology (2014) 64:577-84. doi:10.1111/his.12294
60. Guadamillas MC, Cerezo A, Del Pozo MA. Overcoming anoikis - pathways to anchorage-independent growth in cancer. J Cell Sci (2011) 124:3189-97. doi:10.1242/jcs.072165
61. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol (2005) 16:189-94. doi:10.1093/annonc/mdi057
62. Capdevila J, Carrato A, Tabernero J, Grande E. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer? Crit Rev Oncol Hematol (2014) 92(2):83-106. doi:10.1016/j.critrevonc.2014.05.004
63. Malaguarnera R, Belfiore A. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells. Front Endocrinol (Lausanne) (2014) 5:10. doi:10.3389/fendo.2014.00010
64. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev (2009) 28:151-66. doi:10.1007/s10555-008-9179-y
65. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature (1999) 401:173-7. doi:10.1038/43686
66. Wu K, Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol (2009) 29:241-54. doi:10.1615/CritRevImmunol.v29.i3.40
67. Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer. Br J Cancer (2013) 108:2088-96. doi:10.1038/bjc.2013.197
68. Dawson H, Grundmann S, Koelzer VH, Galvan JA, Kirsch R, Karamitopoulou E, et al. Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. Histopathology (2014). doi:10.1111/his.12603
69. Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. OncoTargets Ther (2013) 6:1347-61. doi:10.2147/OTT.S36109
70. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res (2010) 16:2927-31. doi:10.1158/1078-0432.CCR-09-2329
71. Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S. Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. Am J Clin Pathol (2009) 132:202-10. doi:10.1309/AJCPK35VZJEWCUTL
72. Lorentz O, Duluc I, Arcangelis AD, Simon-Assmann P, Kedinger M, Freund JN. Key role of the Cdx2 homeobox gene in extracellular matrix-mediated intestinal cell differentiation. J Cell Biol (1997) 139:1553-65. doi:10.1083/jcb.139.6.1553
73. Guo RJ, Funakoshi S, Lee HH, Kong J, Lynch JP. The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex. Carcinogenesis (2010) 31:159-66. doi:10.1093/carcin/bgp213
74. Hinkel I, Duluc I, Martin E, Guenot D, Freund JN, Gross I. Cdx2 controls expression of the protocadherin Mucdhl, an inhibitor of growth and beta-catenin activity in colon cancer cells. Gastroenterology (2012) 142:875-85.e3. doi:10.1053/j.gastro.2011.12.037
75. Funakoshi S, Kong J, Crissey MA, Dang L, Dang D, Lynch JP. Intestine-specific transcription factor Cdx2 induces E-cadherin function by enhancing the trafficking of E-cadherin to the cell membrane. Am J Physiol Gastrointest Liver Physiol (2010) 299:G1054-67. doi:10.1152/ajpgi.00297.2010
76. Brabletz T, Spaderna S, Kolb J, Hlubek F, Faller G, Bruns CJ, et al. Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression. Cancer Res (2004) 64:6973-7. doi:10.1158/0008-5472.CAN-04-1132
77. Bayrak R, Yenidunya S, Haltas H. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol Res Pract (2011) 207:156-60. doi:10.1016/j.prp.2010.12.005
78. Helfand BT, Chang L, Goldman RD. Intermediate filaments are dynamic and motile elements of cellular architecture. J Cell Sci (2004) 117:133-41. doi:10.1242/jcs.00936
79. Galvan JA, Helbling M, Koelzer VH, Tschan MP, Berger MD, Hadrich M, et al. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget (2015) 20:874-85.
80. Celesti G, Di Caro G, Bianchi P, Grizzi F, Basso G, Marchesi F, et al. Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors. Gastroenterology (2013) 145:647-57.e15. doi:10.1053/j.gastro.2013.05.011
81. Karagiannis GS, Treacy A, Messenger D, Grin A, Kirsch R, Riddell RH, et al. Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts. Mol Oncol (2014) 8:1240-52. doi:10.1016/j.molonc.2014.04.004
82. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: a promising parameter in colorectal cancer. Br J Cancer (2012) 106:1713-7. doi:10.1038/bjc.2012.127
83. Zlobec I, Terracciano L, Jass JR, Lugli A. Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch (2007) 451:763-9. doi:10.1007/s00428-007-0466-8
84. Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors. World J Gastroenterol (2009) 15:5898-906. doi:10.3748/wjg.15.5898